The Czech Republic's Psilocybin Guidelines

By Dr Mourad Wahba

I'm a fan of the Czechs.

Not for the beauty of Prague or the country’s literary contributions to the world; impressive as they are. My appreciation in this instance is more specific than that, mainly of their psychedelic research group.

Since I first met them around 2018, I have found them to be consistently innovative, scientifically rigorous, well-informed, and above all, playful. They were always a fun group at conferences, and they always seemed to have an impressive balance between having a good time, and showing up fully.

When I heard they had managed to push through legislation permitting psilocybin use under special circumstances, I was not at all surprised. They had been building towards it for years, accumulating experience through their ketamine clinics and a pioneering clinical trials unit. And when I heard they had produced formal clinical guidelines to accompany the legislation, I knew it would be a worthwhile read.

I was not disappointed. The document reflects everything I know of this group: measured, thoughtful, clear, and practical. I think it is an excellent model; elegant in its simplicity and flexibility. In this article, I will summarise its key points and briefly consider what might be applicable in a UK context.

Legal Framework

Use of therapeutic psilocybin in the Czech Republic is governed by three interrelated legal instruments:

• The Healthcare Services Act, which stipulates that healthcare must be delivered in accordance with current scientific knowledge, using recognised medical procedures, and with respect for patient individuality.

• The Addictive Substances Act, which defines the conditions for therapeutic psilocybin use, specifies requirements such as medical supervision, clinician qualifications, and documentation standards, and explicitly states that administration must follow this clinical guideline.

• Government Regulation No. 552/2025, which specifies that psilocybin-containing medicinal products may only be prescribed and administered in accordance with this clinical guideline.

This is significant: adherence to these guidelines is not optional. Any clinician administering psilocybin therapeutically is legally required to comply with them.

Patient Population and Indications

The guidelines state that treatment is intended for patients for whom available treatments have proven ineffective or intolerable. This sounds restrictive at first glance, but closer reading reveals considerably more flexibility than that phrase implies.

One of the listed indications is depression in the context of oncological disease or confrontation with a life-threatening diagnosis, which is characterised by existential distress, fear of death, demoralisation, and secondary depressive symptoms. Here, patients need only have tried one antidepressant to be eligible. This lower threshold is explicitly justified by the condition's poor response to pharmacotherapy and the substantial evidence base in this population.

The second primary indication is clinically significant depressive disorder, moderate to severe episodes. Eligibility criteria include a duration of at least six months and one of the following: failure of two antidepressants; failure of one and intolerance to two; intolerance to three; or failure of one pharmacological and one non-pharmacological modality, all with significant functional impairment and reduced quality of life. The range of pathways into treatment here is notable: it means psilocybin can be offered relatively early in the treatment algorithm, before depression becomes chronic and progressively more resistant to intervention.

Beyond these two primary indications, additional conditions may be considered where the disorder is serious and life-threatening, and standard treatments have failed. These include Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, Generalised Anxiety Disorder, chronic pain syndromes, cluster headache, irritable bowel syndrome, eating disorders, and substance use disorders.

For substance use disorders specifically, treatment is only available for patients who are in residential or structured treatment, currently abstinent, have failed at least one prior residential programme, and are engaged in intensive psychotherapy.

It is worth noting that the evidentiary threshold for these additional indications is relatively low; one randomised controlled trial or a prospective cohort study is sufficient. This appears to be balanced by the strictness of the eligibility criteria and the requirement that the prescribing physician document the evidence base and include justification in both the medical records and the informed consent process.

Contraindications

The guidelines list several absolute contraindications. Key psychiatric contraindications include psychotic disorders, bipolar type I disorder, active substance dependence, pregnancy and breastfeeding (requiring a 24 hour interruption period) and current use of monoamine oxidase inhibitors.

Physical contraindications include a range of cardiovascular conditions; severe cardiovascular disease, acute heart failure, recent myocardial infarction (heart attack) or stroke (within 6 months), as well as intracranial hypertension (high pressure around the brain) and tumours in the central nervous system. Known allergy to psilocybin is also listed.

Other cautions include history of seizures, respiratory insufficiency, and conditions where increased blood pressure poses a risk. Here the guideline emphases the need for clinical judgement and, where relevant, specialist supervision for patients with significant comorbidities.

Notably, complex PTSD and personality disorders are not excluded, which is a genuine strength in my opinion. These populations are routinely excluded from clinical trials, meaning the evidence base is sparse, however the specialist nature of the treating centres means that complications, if they arise, can be identified and managed.

The Service Model

The treatment paradigm is built around specialist teams with clearly defined structures. The service assumes responsibility for patient care throughout the therapeutic process before transferring back to the referring team with a full report.

Team Structure

The guidelines define a clear multidisciplinary structure, though a single clinician may hold more than one role. These roles include:

1. Assessing clinician: The clinician responsible for assessing indications, contraindications, and suitability. Must be a licensed psychiatrist.

2. Prescribing clinician: The clinician who can prescribe and administer the dose. This can be a licensed psychiatrist or a clinician with secondary specialisation in psychotherapy.

3. Supervising physician: Present throughout dosing sessions to provide medical oversight and intervene if needed. Must be a psychiatrist, a physician with psychotherapy training, or a physician with psychedelic-assisted psychotherapy (PAP) training. More junior clinicians may fulfil this role under supervision, provided a senior medic is available within five minutes.

4. Lead therapist: Takes the lead in facilitating sessions; at least one must be present throughout, with pairs recommended. Must be a clinical psychologist or psychiatrist with psychotherapy training, and specifically trained in PAP. Space exists for a physician or psychologist to fulfil this role under direct supervision.

5. Second therapist: A healthcare professional with psychotherapy training. May be in training, provided they work under supervision.

Training Requirements

The guidelines set out detailed training requirement, which reflects both the early stage of the field and the recognition that most prior experience was acquired within clinical trials. Eligible practitioners are limited to psychiatrists, physicians with psychotherapy training, and clinical psychologists working within healthcare settings. Facilitators without clinical or formal training are explicitly excluded, a deliberate decision to ensure that PAP-specific skills are built on a solid foundation of clinical knowledge. Only psychotherapy training recognised within healthcare systems is valid.

Training programmes must be approved by the Ministry of Health or the Czech Neuropharmacological Society. The minimum PAP training requirement is six months in duration, comprising more than 100 hours of theory and practice, and including supervised clinical sessions and case discussions. Curricula must cover neuropsychology and phenomenology of altered states, mechanisms of action, safety and pharmacovigilance, set and setting, body-based work, crisis management, and legal requirements, among other areas. Training is under-way with cohorts having started in the recent past.

Specific requirements apply to different roles. Programme Directors (lead trainers), for example, must have at least five years of full-time PAP or ketamine-assisted psychotherapy (KAP) experience, a minimum of 50 sessions as prescribing physician, facilitator, or lead therapist, at least 30 hours of supervision, familiarity with standard operating procedures, adverse event monitoring, and basic life support competency. Teaching faculty must have at least one year of PAP or KAP experience, at least 20 completed sessions, training in crisis management, and demonstrable real-world clinical experience.

A transition provision allows experienced practitioners to qualify without formal PAP training if they can demonstrate relevant clinical experience from trials, with minimum session thresholds set for each role.

This is particularly interesting as it acknowledges the limited venues where experience in PAP can be acquired, and clinical trials are utilised here as a training ground where experience can be evidenced.

Pre-Treatment Work-Up

Work-up of patients includes a full psychiatric assessment with focus on diagnosis, review of current pharmacotherapy, suitability for PAP, a comprehensive risk assessment, and excluding contraindications. Physical health assessment is also completed, including ECG, full blood count, CRP, U&Es, lipid profile, and thyroid function tests.

Treatment Protocols

Three distinct treatment pathways are available:

1. Single-dose model: One dose is administered, followed by a minimum three-week evaluation period before any further session is considered.

2. Repeated fixed dosing: Multiple sessions at a fixed dose, with a minimum seven-day interval between sessions. A cap of three sessions per month and 75 mg total per month applies.

3. Dose escalation model: A start low, go slow approach, going up in dose across sessions and adjusted based on patient response and preference.

A single-session maximum of 35 mg applies across all pathways, and the first dose a patient receives may not exceed 25 mg.

Model choice depends on patient response, tolerability, and patient preference.

Maintenance/Repeated Use

Minimum interval of 8 weeks before another regime is prescribed, guided by relapse risk and clinical deterioration.

Dosing Structure

Dosing is weight-based, typically 0.2–0.4 mg/kg administered orally, and is categorised according to intended clinical effect. The table below summarises the dosing hierarchy:

Category	Dose	Clinical Effect
Microdose	<2.5 mg	Sub-perceptual; no significant perceptual changes
Low dose	5–15 mg	Mild perceptual changes, increased introspection, early insight
Standard (therapeutic)	20–25 mg	Full psychedelic experience; primary antidepressant effect range
High dose	25–35 mg	Ego dissolution, potential for deep psychological insights
Supra-therapeutic	>35 mg	Research and safety studies only; not for routine clinical use

Preparation

Preparation overall is fairly standard and as one would expect, where patients receive psychoeducational material and are informed on expected effects, risks, treatment process, evidence base, and role of the different staff members within the team.

This also includes an introduction to the patient; exploration of goals, motivations and expectations, and building therapeutic alliance. It focuses on different aspects that are handy for the psychedelic experience, including openness to experience, managing uncertainty, and navigating altered states, with techniques such as grounding, body awareness, and working with internal imagery.

At least two preparation sessions are required, with a total duration of 180 minutes.

Dosing

A full physical and mental state assessment is conducted prior to dosing, with focus on vital signs, pregnancy, mental state stability, and substance use. Precautionary measures are taken for certain conditions. For example, an ACE inhibitor may be administered beforehand to manage blood pressure.

Dosing takes place in a calm, comfortable, aesthetically appealing room without religious or spiritual framing.

For low-dose sessions, patients remain in the clinical setting for a minimum of four hours; for high-dose sessions, this extends to at least six hours. Vital signs are monitored at four defined points: baseline, the peak, the plateau, and the resolution of the experience. A medic is present throughout and must assess participant safety prior to discharge. Patients are advised not to drive and to leave with an escorted or organised transport.

The therapeutic approach here also has some similarities to the clinical trial framework, with a focus on non-directive approach which supports emotional processing and helps manage difficult experiences. Techniques include grounding, breathwork, relaxation methods, and supportive touch.

Integration and Follow-Up

The guidelines specify a minimum of two integration sessions within the ten days following dosing, with the first occurring within 72 hours and the second within 10 days. These are around 60-90 minutes long and focus on consolidating insight and integrating experience into daily life, while aiming to prevent psychological destabilisation. Focus is on linking insight to clinical issues and personal narratives, and to support meaning-making and behavioural change.

Weekly follow-up continues for one month, after which care is transferred back to the patient's usual team with a detailed clinical report.

Adverse Events and Drug Interactions

These are clearly highlighted within the document, and with headache and nausea being the main physical ones, and anxiety, confusion, and fear from a psychological standpoint, which are framed as often part of the therapeutic process. Serious adverse events such as severe psychological distress, panic reactions, and transient psychotic states are also highlighted, but are delineated as ones that are reduced by good preparation and screening. These are then explored in more detail, with protocols for how to manage each individually.

Drug interactions are also explored briefly, with antidepressants generally being accepted to co-administer, but MAOIs contraindicated with a wash-out time suggested. 5HT2A or D2 antagonists should be stopped around 14 days prior to administration as they block the psychedelic effects.

Lessons for the NHS

There is a great deal here that is applicable to an NHS context and some elements that may be more difficult to translate.

First off, the governance. This is directly relevant to the UK as implementation would indeed require strict guidelines to be followed by centres administering psychedelics, with national restrictions to ensure consistency across centres. One thing I would add here is a UK wide register for those who are prescribed them, and a way of directly reporting adverse effects e.g. the Yellow Card reporting site.

I believe the specialist centre model is particularly well suited to an early implementation phase. Concentrating expertise in defined units means teams can accumulate experience systematically, develop competence in navigating unfamiliar clinical territory, and serve as training grounds for the next cohort of practitioners. Group administration and other innovative formats can be explored within a controlled environment before wider adoption.

The most obvious infrastructure for this already exists within the UK. The Mental Health Mission mood disorder clinics form a distributed network of specialist centres across the country; Glasgow, Edinburgh, Newcastle, Sheffield, Oxford, Bristol, Cambridge, London, Exeter, and more. These sites are already conducting psychedelic clinical trials, have trained staff, established pharmacy protocols, and dedicated dosing rooms. Crucially, they accept self-referrals and their clinical leads are connected through active peer networks. They are, in many respects, the foundation that an NHS psychedelic therapy programme could be built upon.

Another initiative worth mentioning is the CNWL-Imperial-Montreal Ketamine Therapy (CIM-KeT) pilot program in London. It has a clever design that also utilises existing NHS structures, albeit differently. Here, patients receiving psychotherapy within talking therapies in primary care are given the opportunity to receive ketamine alongside it for the first five sessions, aiming to enhance and prolong therapeutic outcomes. What’s relevant here is that patients remain within primary care for their treatment, only having the five visits to the ketamine clinic added, reducing overall treatment burden and cost. While I don’t think this directly translates to psilocybin as, in my opinion, it requires more intensive input, I do think it neatly illustrates how one service can seamlessly integrate into another. It may be that a combination of the mood disorder clinics and a modified CIM-KeT model is the way forwards.

The emphasis on training standards within the guidelines is equally important, and equally achievable. The Czech framework is notable for measuring competence not merely through credentials but through hours of supervised practice and documented experience. The mood disorder clinics above are well positioned to provide exactly this kind of training, which is ongoing as we speak. Therapists within the clinics have been trained by trial sponsors to deliver psychedelic therapy, and their credentials and expertise can be transferrable into clinical practice.

While it’s tempting to aim for the quickest and cheapest roll-out, evidence clearly points towards the need for skilled, experienced facilitation, especially in managing intra and post-session difficulties. One such example is a recent naturalistic trial which reported that 31% of participants who experienced post-dosing difficulties showed symptoms consistent with PTSD, 70% of which were attributed to frightening or challenging experiences during the session. Avoidance during the experience was associated with greater symptom severity, and psychotherapy was rated the most helpful intervention(1). Therapists must be well equipped to prepare patients, support them within sessions, and help them navigate any post-session difficulties. A rigorous training programme is therefore a must, especially without the guard rails of clinical trials and their narrow patient profile.

Where the Czech model may be harder to translate is in the evidentiary standards for new indications. The NHS will almost certainly require robust RCT data before approving psilocybin or other psychedelics for any indication, and this process will likely begin with depression and PTSD before gradually expanding to other areas. That said, this field is moving with unusual speed: what seems like a reasonable constraint today may look quite different in a year's time.

Conclusion

The Czech Republic has produced a useful and practical framework for slowly rolling out psilocybin assisted therapy. A clinical framework that is evidence-grounded, practically structured, and flexible enough to accommodate the current state of the evidence and the realities of clinical practice. It does not pretend that all the answers are known, but creates space for specialist teams to develop expertise carefully, with appropriate safeguards, while making treatment available to patients who need it now.

The infrastructure for a comparable UK programme is, at least in my eyes, within arm’s reach. The specialist trial sites exist. The trained clinicians exist. The peer networks exist. What remains is the policy will to bring these elements together into a coherent framework and the Czech example offers a clear and credible template for doing so.

References

1. Evens R, Uyar A, Gosslau E, Dambeck F, Repantis D, Wolff M, et al. Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study. Psychological Medicine. 2026;56:e88.